发明授权
US09044468B2 Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
有权
标记的前列腺特异性膜抗原（PSMA）的抑制剂，生物学评价和用作成像剂
- 专利标题： Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
- 专利标题（中）： 标记的前列腺特异性膜抗原（PSMA）的抑制剂，生物学评价和用作成像剂
-
申请号： US12666441申请日： 2008-06-26
-
公开(公告)号： US09044468B2公开(公告)日： 2015-06-02
- 发明人: Martin G. Pomper , Ray Sangeeta , Ronnie C. Mease , Catherine Foss
- 申请人： Martin G. Pomper , Ray Sangeeta , Ronnie C. Mease , Catherine Foss
- 申请人地址： US MD Baltimore
- 专利权人： THE JOHNS HOPKINS UNIVERSITY
- 当前专利权人： THE JOHNS HOPKINS UNIVERSITY
- 当前专利权人地址： US MD Baltimore
- 代理机构： Ward and Smith, P.A.
- 国际申请： PCT/US2008/007947 WO 20080626
- 国际公布： WO2009/002529 WO 20081231
- 主分类号： A61K51/04
- IPC分类号： A61K51/04 ; A61K31/513 ; A61K31/4402 ; A61K31/145 ; A61K31/195 ; A61K31/395 ; A61K38/06 ; C07D213/38 ; C07D215/12 ; C07D257/00 ; G01N33/574
摘要：
The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.